TACR1 and laryngeal carcinoma: Likewise, the evidence provided in this meta-analysis highlights the interest in the development of in-depth research on targeted therapies directly to the receptor, such as L-773060, a specific NK-1R antagonist that has demonstrated its antitumor activity against different cell lines (gliomas, retinoblastoma, neuroblastoma, melanoma or laryngeal carcinoma) [15,17,18,50,51,52] and aprepitant that has already been tested in humans [25,26,53,54,55].